Venlafaxine in a patient with idiopathic leukopenia and mirtazapine-induced severe neutropenia.
D000380:Agranulocytosis / Q000097:blood / Q000139:chemically induced / Q000453:epidemiology; D018687:Antidepressive Agents, Second-Generation / Q000627:therapeutic use; D000929:Antidepressive Agents, Tricyclic / Q000009:adverse effects* / Q000627:therapeutic use; D015897:Comorbidity; D003511:Cyclohexanols / Q000627:therapeutic use; D003866:Depressive Disorder / Q000097:blood / Q000188:drug therapy*; D004342:Drug Hypersensitivity / Q000453:epidemiology; D005260:Female; D006801:Humans; D007970:Leukopenia / Q000097:blood / Q000453:epidemiology*; D008803:Mianserin / Q000009:adverse effects* / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008875:Middle Aged; D000078785:Mirtazapine; D009503:Neutropenia / Q000097:blood / Q000139:chemically induced* / Q000453:epidemiology; D000069470:Venlafaxine Hydrochloride
D018687:Antidepressive Agents, Second-Generation; D000929:Antidepressive Agents, Tricyclic; D003511:Cyclohexanols; D008803:Mianserin; D000069470:Venlafaxine Hydrochloride; D000078785:Mirtazapine